• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
EMD
Click for more information
9.09% 3.0¢

EMYRIA LIMITED - News & Media

Market Cap $12.46M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Emyria Limited is an Australia-based early-stage drug development company. The Company is... Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises medication-assisted treatment programs and biopharmaceuticals, specifically methylenedioxy-methylamphetamine (MDMA) analogues and Ultra-Pure cannabidiol (CBD) capsules. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Little Green Pharma (ASX:LGP) reports record revenue growth, European market expansion and strategic cost savings

Articles & Videos

Emyria, UWA seek commercialisation of compounds to treat PTSD and Parkinson's

Emyria and the University of Western Australia have formed a partnership to secure global rights to a library of patented compounds.

31 Oct 2024 11:18 (AEDT)

Emyria jumps 10% on 'interim' success treating PTSD patients with MDMA

Shares in MDMA psychotherapy player Emyria (ASX:EMD) jumped 9.4% to 3.5cps on Monday following reports of 'interim' success treating patients with PTSD.

02 Sep 2024 10:53 (AEST)

Emyria and UWA secure $499,411 grant to advance MDMA analogue drug program

Emyria Ltd has been awarded a grant of $499,411 to advance its MDMA analogue drug development program to treat a range of conditions.

01 Jul 2024 12:17 (AEST)

Emyria's Empax Centre chosen for mental health clinical trial

Emyria's newly inaugurated Empax Centre has been selected as a key site for a clinical trial sponsored by New York-based Transcend Therapeutics.

20 Jun 2024 10:25 (AEST)

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair has funded the company $0.3M on Tuesday.

23 Apr 2024 12:42 (AEST)

Emyria launches Empax Centre - pioneering innovation in mental health treatment

Emyria Limited has opened the Empax Centre, a cutting-edge facility designed to advance innovative mental health treatments, including psychedelic-assisted therapies.

10 Apr 2024 12:13 (AEST)

Emyria hits milestone in PTSD treatment with first female specialist for MDMA therapy

Emyria has nominated its first female psychiatrist to treat post-traumatic stress disorder using the drug ecstasy.

05 Apr 2024 09:58 (AEDT)

Emyria partners with 'Reach Wellness' to support PTSD patients

Emyria has partnered with charity group 'Reach Wellness' to research the effectiveness of using MDMA to assist PTSD patients.

03 Apr 2024 14:11 (AEDT)

Emyria (ASX:EMD) recruits first patient in MDMA-assisted therapy trial for PTSD

Emyria (ASX:EMD) has recruited the first patient in its phase 2B MDMA-assisted therapy trial for post-traumatic stress disorder (PTSD).

10 Jul 2023 12:47 (AEST)

Emyria (ASX:EMD) to acquire leading psychological trauma care service Pax Centre

Emyria (ASX:EMD) has announced a strategic acquisition of the Pax Centre, enhancing its patient-centric clinical service portfolio.

03 Jul 2023 14:31 (AEST)



(20min delay)
Last
3.0¢ 		Change
-0.003(9.09%) 		Mkt cap ! $12.46M
Open High Low Value Volume
3.1¢ 3.1¢ 3.0¢ $8.437K 272.3K

Buyers (Bids)

No. Vol. Price($)
8 448106 3.0¢
 

Sellers (Offers)

Price($) Vol. No.
3.3¢ 65063 2
View Market Depth
Last trade - 11.44am 07/11/2024 (20 minute delay) ?
Last
3.1¢ 		  Change
-0.003 ( 0.00 %)
Open High Low Volume
3.1¢ 3.1¢ 3.1¢ 30891
Last updated 11.22am 07/11/2024 ?
EMD (ASX) Chart

Top Stories

C29 Metals wins Kazakhstani uranium drill run green tick, Kazatomprom talks mature

C29 Metals appears to be making an eye catching relationship work in its favour – one with Kazakhstani uranium producer Kazatomprom.
Palladium's the newest geopolitical hot commodity. But ASX exposure is limited On October 24, the USA reportedly approached its G7 counterparts and proposed a ban on Russian titanium, and, palladium.
The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint Let’s get straight to the point: of all the smallcaps in the Telecommunications index, The Market Ltd could be one of the most overlooked.
Aerospace smallcap Quickstep Holdings jumps nearly 100% after 40cps takeover offer Quickstep Holdings (ASX:QHL) has received a takeover offer for 40cps, sending shares 100% higher as the stock doubled its price on Thursday.
Pantera begins drilling of maiden test well at Smackover Pantera Minerals Ltd has commenced drilling of its first test well at the Smackover Lithium Brine Project in Arkansas
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.